Abcam, ab264055, Anti-IDH1 (mutated R132G) + IDH2 (mutated R172G) antibody [MsMab-1]

Size: 20µg / 100µg / 1mg
Mouse Recombinant Monoclonal IDH1 mutated R132G antibody. Suitable for ELISA, WB and reacts with Human samples. Cited in 2 publications.
Key facts
Host species:Mouse,
Clonality:Monoclonal,
Clone number:MsMab-1,
Isotype:IgG2a,
Carrier free:No,
Reacts with:Human,
Applications:ELISA, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:The antibody also showed the cross reactivity with other mutants of IDH1 and IDH2.

Product details:
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
IDH1 and IDH2 also known as isocitrate dehydrogenase 1 and 2 play important roles in cellular metabolism. IDH1 has an approximate molecular mass of 45 kDa and is primarily expressed in the cytoplasm and peroxisomes whereas IDH2 with a similar mass is mainly localized in the mitochondria. These enzymes catalyze the oxidative decarboxylation of isocitrate to alpha-ketoglutarate coupled with the conversion of NADP+ to NADPH. This reaction contributes to cellular energy production and antioxidant defense.
Biological function summary
The IDH1 and IDH2 enzymes function by maintaining cellular redox balance and providing reductive power for biosynthesis. They also participate as part of the tricarboxylic acid (TCA) cycle where their enzymatic activity is important for the continuation of this metabolic pathway. The role of IDH1 and IDH2 within the TCA cycle ensures the efficient conversion of nutrients into energy. Their activity reflects a direct influence on central metabolic processes including lipid biosynthesis glucose metabolism and the generation of cellular building blocks.
Pathways
Both IDH1 and IDH2 are fundamental components of the TCA cycle and are also involved in the reductive carboxylation pathway. Their function involves key interactions with other metabolic proteins such as alpha-ketoglutarate dehydrogenase which also feeds into the TCA cycle. Fatty acid synthesis and glutamine metabolism pathways also align with IDH1 and IDH2 functions linking them to essential cellular processes that balance energy production with biosynthetic needs.
IDH1 and IDH2 mutations have been strongly associated with gliomas and acute myeloid leukemia (AML). These mutations significantly alter the normal enzymatic activity leading to the production of the oncometabolite 2-hydroxyglutarate. This metabolite disrupts cellular metabolism and epigenetic regulation contributing to cancer progression. Furthermore the dysfunctional IDH enzymes connect with dysfunctional TET (Ten-Eleven Translocation) proteins which are involved in DNA methylation and gene expression regulation highlighting their involvement in tumorigenesis.